ММВБ 2 424 2,5%  Nasdaq 11 985 2,8%  Биткойн 30 196 -0,8%  USD/RUB 63,7250 -2,7% 
РТС 1 201 2,3%  S&P500 4 089 2,0%  Нефть 112,5 -0,3%  EUR/RUB 67,1439 -2,9% 
Dow 32 655 1,3%  FTSE100 7 518 0,7%  Золото 1 812 -0,2%  EUR/USD 1,0537 -0,2% 

BioNTech (ADRs) - Профиль

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Акционеры

Название Доля (%)
Freefloat101,75
Vanguard Capital Opportunity Fund0,92
PRIMECAP Odyssey Aggressive Growth Fund0,68

Адрес

а/я:
Телефон:
Факс:
Вэб:

Менеджмент

Добавить или редактировать инструмент